中国医药制造业产业安全及其评价研究
|
摘要
在经济全球化和区域经济一体化进程的推动下,各国在关注以军事安全、政治安全为核心的传统安全的同时,对以经济安全、环境安全、能源安全、公共卫生安全等为内容的所谓非传统安全也越来越重视,作为经济安全中的重要部分产业安全也日益重要。医药制造业是国民经济的重要组成部分,是一个涉及国计民生和公共健康的敏感产业,对于保护和增进人民健康、提高生活质量,对计划生育、军需战备以及促进经济发展和社会进步均具有十分重要的作用,尤其对于世界上最大的发展中国家中国来说,医药制造业的产业安全尤其重要。因此系统分析中国医药制造业的产业安全及其评价问题具有重要理论价值和现实意义。
论文以产业安全理论为基础,综合运用经济学、管理学、可拓工程理论,探讨了中国医药制造业安全理论;详细分析了中国医药制造业的发展效率和产业安全的影响要素;给出中国医药制造业产业安全评价指标体系,应用了改进的层次分析法建立了中国医药制造业产业安全评价指标的权重;结合可拓工程的知识,用分层可拓评价法建立了中国医药制造业产业安全评价模型并进行了实证研究;依据评价结果针对性得提出政策建议。
通过对中国医药制造业产业安全理论的研究,了解了中国医药制造业的特点、发展历程、现状和特点;在介绍了医药制造业产业安全相关理论后,定义了中国医药制造业产业安全的内涵,并认为医药制造业产业安全具有动态性、系统性、综合性和战略性等特点。通过对中国医药制造业产业安全影响因素的研究,认为医药产业安全的影响因素可以分为间接动力因素和直接来源因素两部分,直接来源因素表现为产业现实的国际竞争能力和自主创新能力,间接动力因素表现为产业要素、市场需求、产业国际化和政府的作用,创造了综合上述六种要素的医药制造业产业安全影响要素的“金盾”模型。在研究中国医药制造业产业安全评价指标体系中,把医药自主创新能力作为影响中国医药制造业产业安全的一个关键影响因素来考虑,在丰富中国医药制造业产业安全理论方面进行了尝试。通过专家意见调查获得的资料,并应用了改进的层次分析法分析建立了中国医药制造业产业安全评价指标的权重。在对中国医药制造业产业安全评价模型的研究中,根据中国医药制造业产业安全评价的特点,采用了分层可拓评价方法,构建了基于可拓工程的中国医药制造业产业安全分层可拓评价模型。依据评价模型,对中国医药制造业的产业安全度进行了科学实证评价,认为中国医药制造业产业整体的产业安全度虽处于薄弱的基本安全状态,但是最关键的医药自主创新能力因素和医药制造业国际竞争力处于危机状态。最后,基于以上问题的研究,从优化中国医药制造业发展环境、提高中国医药制造业自主创新能力、提升中国医药制造业国际竞争力三个方面提出对策建议。
Driven by the progress of economic globalization and regional economic integration, all countries are paying more and more attention to so-called non-traditional securities including economy, environment, energy, culture, information and public health, etc. meanwhile focusing on such traditional securities as military security and political security. As important part in economic security, industrial security is becoming more and more important. Pharmaceutical industry is an important component in the national economy, being a sensitive industry involving in national welfare and people’s livelihood and public health. It plays an essential role in family planning, disaster and epidemic prevention, military demand preparation as well as advocating economic development and social improvement. It combines traditional industry and modern industry, being an industry closely related to first, second and third industries. The security of pharmaceutical industry is extremely important for China, the largest developing country with more than 1.3 billion population. It is significant for enriching theories of industrial security and exploring evaluation methods of industrial security to systematically analyze the influential factors, scientifically evaluate the industrial security status and look for feasible measures to enhance the security of the Chinese pharmaceutical industry.
Based on the theory of industrial security, the thesis paper has comprehensively applied theories of economics, management and extension methods to discuss the theory of security of Chinese pharmaceutical industry; specifically analyzed the development efficiency of the Chinese pharmaceutical industry and the influential factors of industrial security; given evaluation index system to the industrial security of Chinese pharmaceutical industry and use the method of analytic hierarchy proeess(AHP) of improvement to establish the weight of the evaluation index system to the industrial security of Chinese pharmaceutical industry. The paper has also combined the knowledge of extension engineering to carry out an evaluation on the industrial security of Chinese pharmaceutical industry with the method of analytic hierarchy proeess(AHP) of improvement. According to the evaluation result, countermeasures for improving the security of Chinese pharmaceutical industry have been given persistently.
First, comprehensive summary has been given to the development process of the industrial security theory as well as connotations, characteristics, causes and evaluation methods of domestic and foreign experts to industrial security at present, pointing out the insufficiencies in the research. Second, DEA model has been used to analyze the development efficiency of the Chinese pharmaceutical industry, meanwhile based on the theory of industrial security, aiming at the characteristics and the current situation of the Chinese pharmaceutical industry, researches have been done on definitions, connotations and basic characteristics of the security of Chinese pharmaceutical industry. Third, based on the theory of industrial security, the“golden shield”model of influential factors on the security of pharmaceutical industry has been established. At the same time, as one critical influential factory to the Chinese pharmaceutical industry, independent creativity has been taken into sufficient consideration to make attempts on the enrichment of security theory of Chinese pharmaceutical industry. Fourth, according to the index system design principle with combination of connotations, characteristics and influential factors of the security of Chinese pharmaceutical industry, the evaluation index system for security of Chinese pharmaceutical industry has been established, which systematically analyzes the current situations of all indexes of security of the Chinese pharmaceutical industry. Improved analytic hierarchy proeess(AHP) method has been used to establish the weight of the evaluation index system to the industrial security of Chinese pharmaceutical industry. Fifth, aiming at the characteristics of security evaluation of the Chinese pharmaceutical industry, separate extension evaluation method has been used to structure the separate extension evaluation model of the security of Chinese pharmaceutical industry based on extension engineering, and general situation of the security of Chinese pharmaceutical industry has been scientifically evaluated. According to the evaluation model, evaluation has been carried out and a brand-new conclusion has been drawn on the security of Chinese pharmaceutical industry. At last, based on the evaluation system and the evaluation result, the countermeasures and strategies for improving the security of the pharmaceutical industry have been researched persistently.
论文以产业安全理论为基础,综合运用经济学、管理学、可拓工程理论,探讨了中国医药制造业安全理论;详细分析了中国医药制造业的发展效率和产业安全的影响要素;给出中国医药制造业产业安全评价指标体系,应用了改进的层次分析法建立了中国医药制造业产业安全评价指标的权重;结合可拓工程的知识,用分层可拓评价法建立了中国医药制造业产业安全评价模型并进行了实证研究;依据评价结果针对性得提出政策建议。
通过对中国医药制造业产业安全理论的研究,了解了中国医药制造业的特点、发展历程、现状和特点;在介绍了医药制造业产业安全相关理论后,定义了中国医药制造业产业安全的内涵,并认为医药制造业产业安全具有动态性、系统性、综合性和战略性等特点。通过对中国医药制造业产业安全影响因素的研究,认为医药产业安全的影响因素可以分为间接动力因素和直接来源因素两部分,直接来源因素表现为产业现实的国际竞争能力和自主创新能力,间接动力因素表现为产业要素、市场需求、产业国际化和政府的作用,创造了综合上述六种要素的医药制造业产业安全影响要素的“金盾”模型。在研究中国医药制造业产业安全评价指标体系中,把医药自主创新能力作为影响中国医药制造业产业安全的一个关键影响因素来考虑,在丰富中国医药制造业产业安全理论方面进行了尝试。通过专家意见调查获得的资料,并应用了改进的层次分析法分析建立了中国医药制造业产业安全评价指标的权重。在对中国医药制造业产业安全评价模型的研究中,根据中国医药制造业产业安全评价的特点,采用了分层可拓评价方法,构建了基于可拓工程的中国医药制造业产业安全分层可拓评价模型。依据评价模型,对中国医药制造业的产业安全度进行了科学实证评价,认为中国医药制造业产业整体的产业安全度虽处于薄弱的基本安全状态,但是最关键的医药自主创新能力因素和医药制造业国际竞争力处于危机状态。最后,基于以上问题的研究,从优化中国医药制造业发展环境、提高中国医药制造业自主创新能力、提升中国医药制造业国际竞争力三个方面提出对策建议。
Driven by the progress of economic globalization and regional economic integration, all countries are paying more and more attention to so-called non-traditional securities including economy, environment, energy, culture, information and public health, etc. meanwhile focusing on such traditional securities as military security and political security. As important part in economic security, industrial security is becoming more and more important. Pharmaceutical industry is an important component in the national economy, being a sensitive industry involving in national welfare and people’s livelihood and public health. It plays an essential role in family planning, disaster and epidemic prevention, military demand preparation as well as advocating economic development and social improvement. It combines traditional industry and modern industry, being an industry closely related to first, second and third industries. The security of pharmaceutical industry is extremely important for China, the largest developing country with more than 1.3 billion population. It is significant for enriching theories of industrial security and exploring evaluation methods of industrial security to systematically analyze the influential factors, scientifically evaluate the industrial security status and look for feasible measures to enhance the security of the Chinese pharmaceutical industry.
Based on the theory of industrial security, the thesis paper has comprehensively applied theories of economics, management and extension methods to discuss the theory of security of Chinese pharmaceutical industry; specifically analyzed the development efficiency of the Chinese pharmaceutical industry and the influential factors of industrial security; given evaluation index system to the industrial security of Chinese pharmaceutical industry and use the method of analytic hierarchy proeess(AHP) of improvement to establish the weight of the evaluation index system to the industrial security of Chinese pharmaceutical industry. The paper has also combined the knowledge of extension engineering to carry out an evaluation on the industrial security of Chinese pharmaceutical industry with the method of analytic hierarchy proeess(AHP) of improvement. According to the evaluation result, countermeasures for improving the security of Chinese pharmaceutical industry have been given persistently.
First, comprehensive summary has been given to the development process of the industrial security theory as well as connotations, characteristics, causes and evaluation methods of domestic and foreign experts to industrial security at present, pointing out the insufficiencies in the research. Second, DEA model has been used to analyze the development efficiency of the Chinese pharmaceutical industry, meanwhile based on the theory of industrial security, aiming at the characteristics and the current situation of the Chinese pharmaceutical industry, researches have been done on definitions, connotations and basic characteristics of the security of Chinese pharmaceutical industry. Third, based on the theory of industrial security, the“golden shield”model of influential factors on the security of pharmaceutical industry has been established. At the same time, as one critical influential factory to the Chinese pharmaceutical industry, independent creativity has been taken into sufficient consideration to make attempts on the enrichment of security theory of Chinese pharmaceutical industry. Fourth, according to the index system design principle with combination of connotations, characteristics and influential factors of the security of Chinese pharmaceutical industry, the evaluation index system for security of Chinese pharmaceutical industry has been established, which systematically analyzes the current situations of all indexes of security of the Chinese pharmaceutical industry. Improved analytic hierarchy proeess(AHP) method has been used to establish the weight of the evaluation index system to the industrial security of Chinese pharmaceutical industry. Fifth, aiming at the characteristics of security evaluation of the Chinese pharmaceutical industry, separate extension evaluation method has been used to structure the separate extension evaluation model of the security of Chinese pharmaceutical industry based on extension engineering, and general situation of the security of Chinese pharmaceutical industry has been scientifically evaluated. According to the evaluation model, evaluation has been carried out and a brand-new conclusion has been drawn on the security of Chinese pharmaceutical industry. At last, based on the evaluation system and the evaluation result, the countermeasures and strategies for improving the security of the pharmaceutical industry have been researched persistently.
引文
[1]J. Sperling, E. Kirchner. Economic Security and the Problem of Cooperation in Post-Cold War Europe. Review of International Studies. 1998,(24).
[2]中国现代国际关系研究院经济安全研究中心.国家经济安全[M].北京:时事出版社,2005
[3]俄罗斯B·K·先恰戈夫,国务院发展研究中心国际技术经济研究所译.经济安全—生产、财政、银行[M].中国税务出版社,2003
[4]顾海.医药产业经济学[M].北京:中国医药科技出版社,2006
[5]王维刚.中国医药产业成长特征与机理研究[博士学位论文].同济大学, 2007
[6]费芳.我国制药业的产业组织研究[硕士学位论文].上海师范大学, 2007
[7]袁精华.当前国内外医药行业的形势及特点[J].中国经贸, 2007(11) :66-71
[8]杨亚沙.我国制药业利用外资与自主创新[J].国际经济合作,2009(04):36-40
[9]中国医保商会《中国医药产业安全状况调查报告》。
[10]编委会.国内胰岛素市场解析[J].中国医药技术与市场,2007(5):46-47
[11]张华吉,王翔宇.2007年国产药品批准情况分析[J].中国新药杂志,2007(15):1281-1290
[12]Dimasi J A,Hansen R W,Grabowski H G. The price of innovation: new estimates of drug development costs[J].Journal of Health Economics,2003,22(2):151-186
[13]李学农.国内制药企业新产品研发的现状与对策[J].福建医药杂志,2006,28(1):106
[14]杨易成.我国医药国际化探路[J].中国药物经济学,2007,7(4):12-15
[15]虞忠,卞鹰等.我国中药占国际市场份额的测算及相关概念辨析[J].中国药房,2006(5):328-330
[16]Robert R·Overview of the global herb marketplace[EBOL]·http://www·rirdc·gov au/reports/EOI/04-059·pdf
[17]朱义.基于价值链的医药行业盈利能力研究[J].经济问题,2008(2):46-48.
[18]亚当斯密.国民财富的性质和原因研究,下卷[M].北京:商务印书馆,1979:93
[19]亚当斯密.国民财富的性质和原因研究,下卷[M].北京:商务印书馆,1979:40
[20]Frederic S.Pearson and Simon Payaslian, International Political Economy:Conflict and Cooperation in the Global System, The Mcgraw-Hill Companies,Inc,1999:35
[21]弗里德里希·李斯特.政治经济学的国民体系[M].北京:商务印书馆,1961:118
[22] Timothy W.Stanley,John N.Gllison,Jeffrey W.Frumkin.Mobilizing U.S Industry: A Vanishing Option for National Security? Westview Press, 1987,12
[23]程秀生.在国际竞争中振兴民族经济[J].中国外资,1996(11):7-8
[24]张碧琼.国际资本扩张与经济安全[J].中国经贸导刊,2003(6):30-31
[25]于新东.中国加入WTO后产业保护和产业安全研究及对策[J].学习与探索,2000(2):4-12
[26]杨公朴等.中国汽车产业安全性研究[J].财经研究, 2000(1):22-27
[27]夏兴园,王瑛.国际投资自由化对我国产业安全的影响[J].中南财经大学学报,2001(2):37-41
[28]景玉琴.产业安全概念探析[J].当代经济研究,2004(3):29-31
[29]李连成,张玉波.FDI对我国产业安全的影响和对策探讨[J].新东方,2001(6):21-25
[30]何维达,李冬梅·我国产业安全理论研究综述[J].经济纵横, 2006(8):74-76
[31]王允贵.产业安全问题与政策建议[J].开发导报,1997(1):27-32
[32]程恩富.外商直接投资与民族产业安全[J].财经研究,1998(8):42-44
[33]金碚.产业竞争力与产业安全的关系[J].财经界,2006(6)
[34]景玉琴.产业安全的根本保障:提升民族资本产业控制力[J].福建论坛,2006 (01):30-33
[35]赵世洪.国民产业安全概念初探[J].宏观经济研究,1998(03):15-18
[36]李孟刚.产业安全理论的研究[博士学位论文].北京交通大学,2006年
[37]许铭.中国产业安全问题分析[博士学位论文].复旦大学,2005年
[38]景玉琴.产业安全评价指标体系研究[J].经济学家,2006(02):70-76
[39]方芳.外商直接投资对我国产业安全的威胁及对策[J].上海经济研究,1997(6):35-38
[40]祝年贵.利用外资与中国产业安全[J].财经科学,2003(5):111-115
[41]景玉琴.警惕外资威胁我国产业安全[J].天津社会科学,2006(1):81-84
[42]邓田生,刘慷豪.外商在华垄断性并购对我国产业安全的影响分析[J].现代管理科学,2007,(3):58-59
[43]蒋志敏,李孟刚.外资并购中国企业数量井喷危及产业安全[J].瞭望新闻周刊,2008-7-17
[44]赵广林.经济全球化背景下我国的产业安全[J].南京政治学院学报,2000(2):27-29
[45]黄建军.中国的产业安全问题[J].财经科学,2001(6):1-7
[46]郭春丽.外资并购给我国产业安全带来的隐患透析[J].宏观经济管理,2007(4):44-47
[47]何维达.当前中国三大产业安全的初步估算[J].中国工业经济,2002(2):25-31
[48]朱丽萌.中国农产品进出口与农业产业安全预警分析[J].财经科学,2007(6):111-116
[49]王培志.构建产业安全预警体系保障我国产业安全[J].山东经济战略研究,2008(11):29-31
[50]刘殿国等.基于熵权修正层次分析权的医药产业安全度的生态学评估[J].生态经济,2009(02):54-57
[51]Jassawalla,Avan,Sashittal,Hemant, An examination of collaborationin high一teehnology new Product develoPment Processes[J].The Joumal of Produet InnoovationManagement, 2006,15(3):186一203
[52]United States R&D Poliy for Competitiveness Endless Frontier , limited resources[EB/OL].httP://wwwl2.nist.gov/Pubs/coc_ rd/foreword.html)(R.H.海伊斯(R.H.Hayes)等编写,焦鸿丽、柴成文译.生物制药业[M].北京:中国人民大学出版社,2003:6
[53]Schmied H.,About the quantification of the economic impact of public investments into scientific research,Int J Technol Manage,2008,2(5/6):711–29
[54]逄立艳,姚晓玲等.生物医药信息咨询的发展机会与潜力[J].医学情报工作,2004(4):12-15
[55]上海财经大学课题组, 2006中国产业发展报告[M].上海:上海财经大学出版社,2006(8)
[56]刘志迎,叶蓁,孟令杰.我国高技术产业技术效率的实证分析[J].中国软科学,2007(05):133-137
[57]郑洁,杨昌辉,徐晟.基于SFA的我国医药制造行业技术创新效率研究[J].合肥工业大学学报(社会科学版),2008(04):58-62
[58]吴和成.高技术产业R&D效率分析[J].研究与发展管理,2008(05):83-89
[59]刘建忠.我国医药高新技术产业科技投入绩效评价研究[J].科学管理研究,2009(02):35-38
[60]刘勇,史忠良.我国高技术产业分行业运行效率的实证分析[J].当代财经,2009(06):81-84
[61]许娟,孙林岩,何哲.基于DEA的我国省际高技术产业发展模式及相对优势产业选择[J].科技进步与对策,2009(02):30-33
[62]盛昭翰,朱乔,吴广谋. DEA理论、方法与应用[M].北京:科学出版社, 1996.
[63]CharnesA, CooperW W, Rhodes E.Measuring the efficiency of decision making units [J]. European Journal of Operational Research, 1978 (2): 429-444.
[64]BankerR D, CharnesA, CooperW W. Somemodels for estimating technical and scale inefficiencies in data envelopment a-nalysis[J]. ManagementScience, 1984, 30(9): 1078~1092.
[65]Cooper W W, Seiford L M, Joe Zhu. Handbook on data envelopment analysis [M ]. Boston: Kluwer Academic Publishers, 2004.
[66]迈克尔·波特,竞争优势[M].北京:华夏出版社,1997
[67]刘志迎.现代产业经济学教程[M].北京:科学出版社,2007
[68]Fulvio Castellacci.Innovation and the competitiveness of industries: Comparing the mainstream and the evolutionary approaehes [J] .Technological Forecasting & Social Change 75(2008)984-1006.
[69]Shonefield,A.(1965).Modern caPitalism: The changing balance of Public and PrivatePower [M] .NewYork : Oxford University Press.
[70]Bennis Wai Yip So.Reassessment of the State Role in the Development of High-Tech Industry: A Case Study of Taiwan,s Hsinchu Science Park[J].EASTASIA, Summer 2006,Vol.23,No.2,pp.61-86.
[71]Peter Evans. Embedded autonomy: states and industrial transformation [M]. Princeton,N.J.: Princeton University Press,cl995.
[72]Vibha Pingle .Rethinking the developmental state : India’s industry in comparative perspective [M].New York : St. Martin’s Press,1999.
[73]景玉琴等.创造有利于产业安全的制度环境[J].理论前沿,2004(24):27-28
[74]Daft,R.L.,Sormunen,J.&Parks,D.Chief Executive Scanning,Envi ronmental Characteristics,And Company Performance: An Empirical Study[J].Strategic Management Journal,1988,9(2).
[75]Moore,J.F.Predators and Prey:A New Ecology of Competition[J].Harvard Business Review,1993(3).
[76]Cooke,P. Regional Innovation System:Competitive Regulation In the New Europe [J]. Geoforum, 1992,23(3).
[77]Porter,M.(1998). On competition [M]. Boston,MA : Harvard Business School Press.
[78]Van Opsal,D.(2001).The skills imperative: Talent and US competitiveness[J].Issues in Science and Technology,18(l):51-58.
[79] Himmelberg C, Petersen B. R&D and internal finance: a panel study of small firms in high-tech industries[J]. Review of Economics and Statistics, 1994, 76: 38-51.
[80]Hoshitak, Scharfstein D. Corporate structure, liquidity, and investment: evidence from Japanese industrial groups [J]. Quarterly Journal of Economics, 1991, 106: 33-60.
[81] Bougheas S. Internal vs external financing of R&D [J]. Small Business Economics, 2004, 22: 11-17.
[82]Paul D A, Bronw Ynhh, Andrew A T. Is public R&D a complementor substitute for private R&D?: a review of the econometric evidence [R]. National Bureau of Economic Research Working Paper Series, 1999.
[83]Tadahisa K. R&D subsidy and self-financed R&D: the case of Japanese high-technology start-ups [ J]. Small Business Economics, 2005, 24: 53-62.
[84]大卫·C·莫厄里,理查德·R·纳尔逊.领先之源:七个行业的分析[M].北京:北京人民邮电出版社,2003(7)
[85]金碚,李钢,陈志.加入WTO以来中国制造业国际竞争力的实证分析[J].中国工业经济,2006(10):5-14
[86]李秀香.幼稚产业开放式保护问题研究[M].北京:中国财政经济出版社,2004:9
[87]史忠良.经济全球化与中国经济安全[M].北京:经济管理出版社,2003:171
[88]傅家骥.技术创新学[M].北京:清华大学出版社,1998. 96
[89]王元.企业创新的制度安排[J].嘹望新闻周刊,2005(49):55-56
[90]宋河发.自主创新及创新自主性测度研究[J].中国软科学,2006(6):60-68
[91]Chang P L,Shih C,Hsu C W. Taiwan’s approach to technological change: the case of intergrated circuit design[J]. Technology Analysis and Strategic Management,1993,5(2):173-177
[92]Span M S, Adams M, Souder W E. Improving federal technology commercialization: some recommendations from a field study [ J ].Technology Transfer,1993,18(3/4):63~74
[93]Porter M E. Technology and competitive strategy [A]. Competitive advantage: creating and sustaining superior performance, chapter 5 [Z].New York:Free Press,1985
[94]Chang P L, Hsu C W, Lung S S C. The forecast model for the technology needs of taiw an high-tech industries[R]. 1997
[95]G?多西.技术进步与经济理论[M].北京:经济科学出版社,1992
[96]Fagerberg J.Why growth rates differ //Dosi G,Freem An C,Nelsonr,et al.Technical change and economic theory[M]. London: Printer Publishers, 1988: 432-457
[97]赖明勇,王建华.技术创新对国际竞争力作用评测模型研究[J].预测,1999(1),70-72
[98]景玉琴.开放、保护与产业安全[J].财经问题研究,2005(5):32-37
[99]李孟刚.产业安全[M].浙江大学出版社,2008
[100]王允贵.跨国公司的垄断优势及其对东道国的产业控制——跨国公司对我国电子及通信设备制造业的投资与控[J].管理世界,1998(2):114-121
[101]于新东.产业保护和产业安全的理论分析[J].上海经济研究,1999(11)
[102]王允贵.外资对我国产业安全的影响[J].瞭望1997(3)
[103]何维达.中国“入世”后的产业安全问题及其对策[J].经济学动态,2001(11):40
[104]张旭宏,庞锦.我国外贸依存度分析和政策建议[J].经济研究参考,2005(56):26-28
[105]乔颖,彭纪生,孙文祥.FDI对我国产业风险的实证分析[J].世界经济研究,2005(9)
[106]薛新东.我国医药产业融资模式、问题与对策——基于全国57家医药上市企业的分析[J].中国医药技术经济与管理,2008(8):70-76
[107]Devol R, et a.l Biopharmaceutical Industry Contributions to State and U. S. Economies [R]. Santa Monica, CA: Milken Institute, 2004.
[108]杨易成,杜纲.中国医药产业R&D人力资源发展研究[J].华东经济管理,2009(6)
[109]王维刚,黄崇利.中国医药工业增长与市场需求关系实证研究[J]商业时代,2007(6):97-98.
[110]刘思峰,党耀国,方志耕.灰色系统理论及其应用[M].北京:科学出版社,2004
[111]李凯,马爱霞.我国医药制造业技术创新能力分析[J].中国医药技术经济与管理,2008(10):48-54
[112]Pharmaceutical Research and Manufacturers of America Pharmaceutical Industry Profile 2007 [R]. Washington,DC: PhRMA, 2007.
[113]王玉梅.中国医药产业成长障碍[M].上海:上海人民出版社,2007:100-108
[114]金碚.中国工业国际竞争力——理论、方法与实证研究[J]经济管理出版社,1997
[115]国研网,我国医药外贸呈进口上扬出口低迷趋势,2009-10-30
[116]陈兆奎,申俊龙.我国医药产业集中度的实证研究[J].中国医药导报,2006(34):98-99
[117]Martin Schaaper. OECD划分高技术产业、测度ICT和生物技术产业的方法[J].科技管理研究,2005,(12)
[118]孔欣欣,罗晖.我国高技术产业利润率偏低对产业结构调整的影响及对策研究[J].中国软科学,2007(8):46-55
[119]韦航.跨国制药企业的中国战略[J].WTO经济导刊,2004(Z1):70-71
[120]张世国.跨国公司中国市场的战略进入与国家产业安全,中国经济时报20060727
[121]中国新闻网,外资品牌占据中国药品市场半壁江山,20090812
[122]梁虹等.可拓学理论在水质量综合评价中的应用研究[J].环境污染治理技术与设备,2004,5(7):25-29
[123]谢云层.设备可拓更新理论及方法研究,[博士学位论文],吉林,吉林大学,2007年
[124]蔡文.从物元分析到可拓学[M].北京:科学技术文献出版社,1995:15-40
[125]苗东升.系统科学精要[M].北京:中国人民大学出版社,1998:1-51
[126]魏辉,余永权.可拓检测的物元模型及其实现[J].广东工业大学学报,2001,18(3):17-20
[127]余永权,张吉文.可拓检测的方案生成[J].中国工程科学,2002,4(1):64-68
[128]刘魏,张秀芳.基于可拓信息的知识表示[J].系统工程理论与实践,1998(1):104-108
[129]刘巍,高红,葛维燕,刘文娜.信息物元的度量及可拓信息空间的化简[J].广东工业大学学报,2001,18(10):6-10
[130]张应利,何斌.基于物元可拓性的潜信息挖掘[J].数学的实践与认识,2001,31(9):570-573
[131]杨春燕,蔡文.可拓工程[M].北京:科学出版社,2007:71
[132]李文果,孙雪林,孙森林.基于模糊物元模型上的AHP在水质评价中的应用[J].安徽农业科学,2006(17):4367-4368
[133]隋海荣,房栓社,马福雷.建设项目方案评价的模糊物元模型及其应用[J].基建优化,2006(4):54-56
[134]张斌.模糊物元分析[M].北京:石油工业出版社,1997:112-205
[135]冯丽云,邱林.模糊物元模型在生态园区配水方案优选中的应用[J].华北水利水电学院学报,2006(1):7-10
[136]Saaty T L.Fundamentals of decision making and priority theory with the analytic hierarchy process[M].Pittsburgh: RWS Publications,1994
[137]吴育化,杜纲.管理科学基础[M].天津:天津大学出版社2004:220-241
[138]许树柏.层次分析法原理[M].天津:天津大学出版社,1988:78-80
[139]何维达等.中国纺织工业发展预测及安全度估算[J].山西财经大学学报,2007(29):50-55
[140]何维达,潘玉璋等.中国石化产业安全分析与定量估算[J].经济与管理研究,2009(03):61-65
[141]李冬梅.产业安全的层次综合评价研究[J].科技管理研究,2007(06):93-95.
[142]刘凡,任启芳.我国造纸产业安全性定量分析[J].中华纸业,2008(5):15-20
[143]张广洲,王凤山.对我国新药研发现状的几点思考[J].齐鲁药事,2007,26(1):38
[2]中国现代国际关系研究院经济安全研究中心.国家经济安全[M].北京:时事出版社,2005
[3]俄罗斯B·K·先恰戈夫,国务院发展研究中心国际技术经济研究所译.经济安全—生产、财政、银行[M].中国税务出版社,2003
[4]顾海.医药产业经济学[M].北京:中国医药科技出版社,2006
[5]王维刚.中国医药产业成长特征与机理研究[博士学位论文].同济大学, 2007
[6]费芳.我国制药业的产业组织研究[硕士学位论文].上海师范大学, 2007
[7]袁精华.当前国内外医药行业的形势及特点[J].中国经贸, 2007(11) :66-71
[8]杨亚沙.我国制药业利用外资与自主创新[J].国际经济合作,2009(04):36-40
[9]中国医保商会《中国医药产业安全状况调查报告》。
[10]编委会.国内胰岛素市场解析[J].中国医药技术与市场,2007(5):46-47
[11]张华吉,王翔宇.2007年国产药品批准情况分析[J].中国新药杂志,2007(15):1281-1290
[12]Dimasi J A,Hansen R W,Grabowski H G. The price of innovation: new estimates of drug development costs[J].Journal of Health Economics,2003,22(2):151-186
[13]李学农.国内制药企业新产品研发的现状与对策[J].福建医药杂志,2006,28(1):106
[14]杨易成.我国医药国际化探路[J].中国药物经济学,2007,7(4):12-15
[15]虞忠,卞鹰等.我国中药占国际市场份额的测算及相关概念辨析[J].中国药房,2006(5):328-330
[16]Robert R·Overview of the global herb marketplace[EBOL]·http://www·rirdc·gov au/reports/EOI/04-059·pdf
[17]朱义.基于价值链的医药行业盈利能力研究[J].经济问题,2008(2):46-48.
[18]亚当斯密.国民财富的性质和原因研究,下卷[M].北京:商务印书馆,1979:93
[19]亚当斯密.国民财富的性质和原因研究,下卷[M].北京:商务印书馆,1979:40
[20]Frederic S.Pearson and Simon Payaslian, International Political Economy:Conflict and Cooperation in the Global System, The Mcgraw-Hill Companies,Inc,1999:35
[21]弗里德里希·李斯特.政治经济学的国民体系[M].北京:商务印书馆,1961:118
[22] Timothy W.Stanley,John N.Gllison,Jeffrey W.Frumkin.Mobilizing U.S Industry: A Vanishing Option for National Security? Westview Press, 1987,12
[23]程秀生.在国际竞争中振兴民族经济[J].中国外资,1996(11):7-8
[24]张碧琼.国际资本扩张与经济安全[J].中国经贸导刊,2003(6):30-31
[25]于新东.中国加入WTO后产业保护和产业安全研究及对策[J].学习与探索,2000(2):4-12
[26]杨公朴等.中国汽车产业安全性研究[J].财经研究, 2000(1):22-27
[27]夏兴园,王瑛.国际投资自由化对我国产业安全的影响[J].中南财经大学学报,2001(2):37-41
[28]景玉琴.产业安全概念探析[J].当代经济研究,2004(3):29-31
[29]李连成,张玉波.FDI对我国产业安全的影响和对策探讨[J].新东方,2001(6):21-25
[30]何维达,李冬梅·我国产业安全理论研究综述[J].经济纵横, 2006(8):74-76
[31]王允贵.产业安全问题与政策建议[J].开发导报,1997(1):27-32
[32]程恩富.外商直接投资与民族产业安全[J].财经研究,1998(8):42-44
[33]金碚.产业竞争力与产业安全的关系[J].财经界,2006(6)
[34]景玉琴.产业安全的根本保障:提升民族资本产业控制力[J].福建论坛,2006 (01):30-33
[35]赵世洪.国民产业安全概念初探[J].宏观经济研究,1998(03):15-18
[36]李孟刚.产业安全理论的研究[博士学位论文].北京交通大学,2006年
[37]许铭.中国产业安全问题分析[博士学位论文].复旦大学,2005年
[38]景玉琴.产业安全评价指标体系研究[J].经济学家,2006(02):70-76
[39]方芳.外商直接投资对我国产业安全的威胁及对策[J].上海经济研究,1997(6):35-38
[40]祝年贵.利用外资与中国产业安全[J].财经科学,2003(5):111-115
[41]景玉琴.警惕外资威胁我国产业安全[J].天津社会科学,2006(1):81-84
[42]邓田生,刘慷豪.外商在华垄断性并购对我国产业安全的影响分析[J].现代管理科学,2007,(3):58-59
[43]蒋志敏,李孟刚.外资并购中国企业数量井喷危及产业安全[J].瞭望新闻周刊,2008-7-17
[44]赵广林.经济全球化背景下我国的产业安全[J].南京政治学院学报,2000(2):27-29
[45]黄建军.中国的产业安全问题[J].财经科学,2001(6):1-7
[46]郭春丽.外资并购给我国产业安全带来的隐患透析[J].宏观经济管理,2007(4):44-47
[47]何维达.当前中国三大产业安全的初步估算[J].中国工业经济,2002(2):25-31
[48]朱丽萌.中国农产品进出口与农业产业安全预警分析[J].财经科学,2007(6):111-116
[49]王培志.构建产业安全预警体系保障我国产业安全[J].山东经济战略研究,2008(11):29-31
[50]刘殿国等.基于熵权修正层次分析权的医药产业安全度的生态学评估[J].生态经济,2009(02):54-57
[51]Jassawalla,Avan,Sashittal,Hemant, An examination of collaborationin high一teehnology new Product develoPment Processes[J].The Joumal of Produet InnoovationManagement, 2006,15(3):186一203
[52]United States R&D Poliy for Competitiveness Endless Frontier , limited resources[EB/OL].httP://wwwl2.nist.gov/Pubs/coc_ rd/foreword.html)(R.H.海伊斯(R.H.Hayes)等编写,焦鸿丽、柴成文译.生物制药业[M].北京:中国人民大学出版社,2003:6
[53]Schmied H.,About the quantification of the economic impact of public investments into scientific research,Int J Technol Manage,2008,2(5/6):711–29
[54]逄立艳,姚晓玲等.生物医药信息咨询的发展机会与潜力[J].医学情报工作,2004(4):12-15
[55]上海财经大学课题组, 2006中国产业发展报告[M].上海:上海财经大学出版社,2006(8)
[56]刘志迎,叶蓁,孟令杰.我国高技术产业技术效率的实证分析[J].中国软科学,2007(05):133-137
[57]郑洁,杨昌辉,徐晟.基于SFA的我国医药制造行业技术创新效率研究[J].合肥工业大学学报(社会科学版),2008(04):58-62
[58]吴和成.高技术产业R&D效率分析[J].研究与发展管理,2008(05):83-89
[59]刘建忠.我国医药高新技术产业科技投入绩效评价研究[J].科学管理研究,2009(02):35-38
[60]刘勇,史忠良.我国高技术产业分行业运行效率的实证分析[J].当代财经,2009(06):81-84
[61]许娟,孙林岩,何哲.基于DEA的我国省际高技术产业发展模式及相对优势产业选择[J].科技进步与对策,2009(02):30-33
[62]盛昭翰,朱乔,吴广谋. DEA理论、方法与应用[M].北京:科学出版社, 1996.
[63]CharnesA, CooperW W, Rhodes E.Measuring the efficiency of decision making units [J]. European Journal of Operational Research, 1978 (2): 429-444.
[64]BankerR D, CharnesA, CooperW W. Somemodels for estimating technical and scale inefficiencies in data envelopment a-nalysis[J]. ManagementScience, 1984, 30(9): 1078~1092.
[65]Cooper W W, Seiford L M, Joe Zhu. Handbook on data envelopment analysis [M ]. Boston: Kluwer Academic Publishers, 2004.
[66]迈克尔·波特,竞争优势[M].北京:华夏出版社,1997
[67]刘志迎.现代产业经济学教程[M].北京:科学出版社,2007
[68]Fulvio Castellacci.Innovation and the competitiveness of industries: Comparing the mainstream and the evolutionary approaehes [J] .Technological Forecasting & Social Change 75(2008)984-1006.
[69]Shonefield,A.(1965).Modern caPitalism: The changing balance of Public and PrivatePower [M] .NewYork : Oxford University Press.
[70]Bennis Wai Yip So.Reassessment of the State Role in the Development of High-Tech Industry: A Case Study of Taiwan,s Hsinchu Science Park[J].EASTASIA, Summer 2006,Vol.23,No.2,pp.61-86.
[71]Peter Evans. Embedded autonomy: states and industrial transformation [M]. Princeton,N.J.: Princeton University Press,cl995.
[72]Vibha Pingle .Rethinking the developmental state : India’s industry in comparative perspective [M].New York : St. Martin’s Press,1999.
[73]景玉琴等.创造有利于产业安全的制度环境[J].理论前沿,2004(24):27-28
[74]Daft,R.L.,Sormunen,J.&Parks,D.Chief Executive Scanning,Envi ronmental Characteristics,And Company Performance: An Empirical Study[J].Strategic Management Journal,1988,9(2).
[75]Moore,J.F.Predators and Prey:A New Ecology of Competition[J].Harvard Business Review,1993(3).
[76]Cooke,P. Regional Innovation System:Competitive Regulation In the New Europe [J]. Geoforum, 1992,23(3).
[77]Porter,M.(1998). On competition [M]. Boston,MA : Harvard Business School Press.
[78]Van Opsal,D.(2001).The skills imperative: Talent and US competitiveness[J].Issues in Science and Technology,18(l):51-58.
[79] Himmelberg C, Petersen B. R&D and internal finance: a panel study of small firms in high-tech industries[J]. Review of Economics and Statistics, 1994, 76: 38-51.
[80]Hoshitak, Scharfstein D. Corporate structure, liquidity, and investment: evidence from Japanese industrial groups [J]. Quarterly Journal of Economics, 1991, 106: 33-60.
[81] Bougheas S. Internal vs external financing of R&D [J]. Small Business Economics, 2004, 22: 11-17.
[82]Paul D A, Bronw Ynhh, Andrew A T. Is public R&D a complementor substitute for private R&D?: a review of the econometric evidence [R]. National Bureau of Economic Research Working Paper Series, 1999.
[83]Tadahisa K. R&D subsidy and self-financed R&D: the case of Japanese high-technology start-ups [ J]. Small Business Economics, 2005, 24: 53-62.
[84]大卫·C·莫厄里,理查德·R·纳尔逊.领先之源:七个行业的分析[M].北京:北京人民邮电出版社,2003(7)
[85]金碚,李钢,陈志.加入WTO以来中国制造业国际竞争力的实证分析[J].中国工业经济,2006(10):5-14
[86]李秀香.幼稚产业开放式保护问题研究[M].北京:中国财政经济出版社,2004:9
[87]史忠良.经济全球化与中国经济安全[M].北京:经济管理出版社,2003:171
[88]傅家骥.技术创新学[M].北京:清华大学出版社,1998. 96
[89]王元.企业创新的制度安排[J].嘹望新闻周刊,2005(49):55-56
[90]宋河发.自主创新及创新自主性测度研究[J].中国软科学,2006(6):60-68
[91]Chang P L,Shih C,Hsu C W. Taiwan’s approach to technological change: the case of intergrated circuit design[J]. Technology Analysis and Strategic Management,1993,5(2):173-177
[92]Span M S, Adams M, Souder W E. Improving federal technology commercialization: some recommendations from a field study [ J ].Technology Transfer,1993,18(3/4):63~74
[93]Porter M E. Technology and competitive strategy [A]. Competitive advantage: creating and sustaining superior performance, chapter 5 [Z].New York:Free Press,1985
[94]Chang P L, Hsu C W, Lung S S C. The forecast model for the technology needs of taiw an high-tech industries[R]. 1997
[95]G?多西.技术进步与经济理论[M].北京:经济科学出版社,1992
[96]Fagerberg J.Why growth rates differ //Dosi G,Freem An C,Nelsonr,et al.Technical change and economic theory[M]. London: Printer Publishers, 1988: 432-457
[97]赖明勇,王建华.技术创新对国际竞争力作用评测模型研究[J].预测,1999(1),70-72
[98]景玉琴.开放、保护与产业安全[J].财经问题研究,2005(5):32-37
[99]李孟刚.产业安全[M].浙江大学出版社,2008
[100]王允贵.跨国公司的垄断优势及其对东道国的产业控制——跨国公司对我国电子及通信设备制造业的投资与控[J].管理世界,1998(2):114-121
[101]于新东.产业保护和产业安全的理论分析[J].上海经济研究,1999(11)
[102]王允贵.外资对我国产业安全的影响[J].瞭望1997(3)
[103]何维达.中国“入世”后的产业安全问题及其对策[J].经济学动态,2001(11):40
[104]张旭宏,庞锦.我国外贸依存度分析和政策建议[J].经济研究参考,2005(56):26-28
[105]乔颖,彭纪生,孙文祥.FDI对我国产业风险的实证分析[J].世界经济研究,2005(9)
[106]薛新东.我国医药产业融资模式、问题与对策——基于全国57家医药上市企业的分析[J].中国医药技术经济与管理,2008(8):70-76
[107]Devol R, et a.l Biopharmaceutical Industry Contributions to State and U. S. Economies [R]. Santa Monica, CA: Milken Institute, 2004.
[108]杨易成,杜纲.中国医药产业R&D人力资源发展研究[J].华东经济管理,2009(6)
[109]王维刚,黄崇利.中国医药工业增长与市场需求关系实证研究[J]商业时代,2007(6):97-98.
[110]刘思峰,党耀国,方志耕.灰色系统理论及其应用[M].北京:科学出版社,2004
[111]李凯,马爱霞.我国医药制造业技术创新能力分析[J].中国医药技术经济与管理,2008(10):48-54
[112]Pharmaceutical Research and Manufacturers of America Pharmaceutical Industry Profile 2007 [R]. Washington,DC: PhRMA, 2007.
[113]王玉梅.中国医药产业成长障碍[M].上海:上海人民出版社,2007:100-108
[114]金碚.中国工业国际竞争力——理论、方法与实证研究[J]经济管理出版社,1997
[115]国研网,我国医药外贸呈进口上扬出口低迷趋势,2009-10-30
[116]陈兆奎,申俊龙.我国医药产业集中度的实证研究[J].中国医药导报,2006(34):98-99
[117]Martin Schaaper. OECD划分高技术产业、测度ICT和生物技术产业的方法[J].科技管理研究,2005,(12)
[118]孔欣欣,罗晖.我国高技术产业利润率偏低对产业结构调整的影响及对策研究[J].中国软科学,2007(8):46-55
[119]韦航.跨国制药企业的中国战略[J].WTO经济导刊,2004(Z1):70-71
[120]张世国.跨国公司中国市场的战略进入与国家产业安全,中国经济时报20060727
[121]中国新闻网,外资品牌占据中国药品市场半壁江山,20090812
[122]梁虹等.可拓学理论在水质量综合评价中的应用研究[J].环境污染治理技术与设备,2004,5(7):25-29
[123]谢云层.设备可拓更新理论及方法研究,[博士学位论文],吉林,吉林大学,2007年
[124]蔡文.从物元分析到可拓学[M].北京:科学技术文献出版社,1995:15-40
[125]苗东升.系统科学精要[M].北京:中国人民大学出版社,1998:1-51
[126]魏辉,余永权.可拓检测的物元模型及其实现[J].广东工业大学学报,2001,18(3):17-20
[127]余永权,张吉文.可拓检测的方案生成[J].中国工程科学,2002,4(1):64-68
[128]刘魏,张秀芳.基于可拓信息的知识表示[J].系统工程理论与实践,1998(1):104-108
[129]刘巍,高红,葛维燕,刘文娜.信息物元的度量及可拓信息空间的化简[J].广东工业大学学报,2001,18(10):6-10
[130]张应利,何斌.基于物元可拓性的潜信息挖掘[J].数学的实践与认识,2001,31(9):570-573
[131]杨春燕,蔡文.可拓工程[M].北京:科学出版社,2007:71
[132]李文果,孙雪林,孙森林.基于模糊物元模型上的AHP在水质评价中的应用[J].安徽农业科学,2006(17):4367-4368
[133]隋海荣,房栓社,马福雷.建设项目方案评价的模糊物元模型及其应用[J].基建优化,2006(4):54-56
[134]张斌.模糊物元分析[M].北京:石油工业出版社,1997:112-205
[135]冯丽云,邱林.模糊物元模型在生态园区配水方案优选中的应用[J].华北水利水电学院学报,2006(1):7-10
[136]Saaty T L.Fundamentals of decision making and priority theory with the analytic hierarchy process[M].Pittsburgh: RWS Publications,1994
[137]吴育化,杜纲.管理科学基础[M].天津:天津大学出版社2004:220-241
[138]许树柏.层次分析法原理[M].天津:天津大学出版社,1988:78-80
[139]何维达等.中国纺织工业发展预测及安全度估算[J].山西财经大学学报,2007(29):50-55
[140]何维达,潘玉璋等.中国石化产业安全分析与定量估算[J].经济与管理研究,2009(03):61-65
[141]李冬梅.产业安全的层次综合评价研究[J].科技管理研究,2007(06):93-95.
[142]刘凡,任启芳.我国造纸产业安全性定量分析[J].中华纸业,2008(5):15-20
[143]张广洲,王凤山.对我国新药研发现状的几点思考[J].齐鲁药事,2007,26(1):38